|1.||Thase, Michael E: 7 articles (10/2009 - 01/2002)|
|2.||Trivedi, Madhukar H: 7 articles (08/2005 - 01/2002)|
|3.||Klein, Daniel N: 6 articles (10/2009 - 01/2002)|
|4.||Manber, Rachel: 6 articles (10/2009 - 05/2002)|
|5.||Markowitz, John C: 6 articles (10/2009 - 01/2002)|
|6.||Borian, Frances E: 6 articles (10/2003 - 01/2002)|
|7.||Rush, A John: 6 articles (10/2003 - 01/2002)|
|8.||Keller, Martin B: 6 articles (10/2003 - 01/2002)|
|9.||Kornstein, Susan G: 6 articles (10/2003 - 01/2002)|
|10.||Dunner, David L: 5 articles (10/2003 - 01/2002)|
|1.||Post-Traumatic Stress Disorders (PTSD)
06/01/2004 - "In a repeated-measures analysis of variance with last observation carried forward, patients on nefazodone showed a significant improvement in the percentage change of Clinician-Administered PTSD Scale Total score from baseline compared with those on placebo (P = 0.04; effect size = 0.6). "
04/01/2003 - "Nefazodone treatment led to a significant decrease in PTSD and depressive symptoms (p <.05), an improvement in global subjective sleep quality, and a reduction in nightmares. "
05/01/1998 - "Nefazodone was associated with statistically significant improvement in mean scores on all six rating scales used to assess change from baseline in PTSD symptoms. "
12/01/2002 - "These data suggest that clinical improvement in PTSD patients administered nefazodone may be maintained with continued treatment. "
09/01/1998 - "These preliminary data suggest that nefazodone may be effective in reducing the 3 primary PTSD symptom clusters and may be particularly helpful in improving sleep and decreasing anger."
|2.||Anxiety Disorders (Anxiety Disorder)
05/01/2002 - "This study investigated the comparative efficacy of nefazodone, Cognitive Behavioral Analysis System of Psychotherapy (CBASP), and their combination in improving anxiety symptoms in patients with chronic forms of major depression, including those with a concurrent anxiety disorder. "
01/01/2003 - "The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder."
01/01/2000 - "Use of nefazodone to treat anxiety disorders appears to have promise, although placebo-controlled studies are still needed. "
01/01/1996 - "An open trial of nefazodone in adult patients with generalized anxiety disorder."
01/01/2003 - "Eleven consenting outpatients with treatment-resistant depression and/or comorbid anxiety disorders were treated with nefazodone, slowly added to their ongoing treatment regimens. "
|3.||Major Depressive Disorder (Major Depressive Disorders)
01/01/1990 - "Results of a multicenter, double-blind, fixed-dose trial indicate nefazodone is effective in improving depressive symptoms of outpatients with major depressive disorder treated with daily doses of 100 mg to 200 mg. A comparison of the fixed-dose trial design with an alternative design permitting dose titration within fixed ranges is presented. "
08/01/2005 - "Data for 996 patients with major depressive disorder (DSM-III-R criteria), who participated in a 12-week acute phase study with nefazodone, were subjected to a post hoc analysis of changes in symptom cluster scores. "
01/01/2004 - "A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment."
04/01/1999 - "This study examined the efficacy and tolerability of nefazodone in an open 12-week trial of HIV-seropositive outpatients with major depressive disorder. "
04/01/1999 - "Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone."
|4.||Sleep Initiation and Maintenance Disorders (Insomnia)
06/01/2002 - "Patients receiving nefazodone (either alone or in combination with CBASP) obtained significantly more rapid and greater ultimate improvement in insomnia ratings when compared with those treated with CBASP alone. "
11/01/2004 - "For a definite evaluation of the possible role of nefazodone in the treatment of primary (psychophysiological) insomnia, double-blind, placebo-controlled, randomized studies with lower doses are needed."
11/01/2004 - "The present study is the first to investigate the effect of the antidepressant nefazodone on sleep in patients with primary (psychophysiological) insomnia. "
03/01/1999 - "The study was a single-center, single-blind, 6-week treatment of nefazodone hydrochloride followed by placebo withdrawal in 16 subjects meeting the DSM-IV criteria for depression who had a score of at least 18 on the 17-item Hamilton Depression Rating Scale, with insomnia-related items 4, 5, and 6 having a total score of 3 or greater. "
11/01/2004 - "Nefazodone in primary insomnia: an open pilot study."
|5.||Phobic Disorders (Phobia)
01/01/1998 - "Results from this case series suggest that nefazodone may be an effective treatment for social phobia and that formal randomized trials are warranted."
02/01/1999 - "This study attempted to assess the efficacy of nefazodone, a new novel serotonergic drug, in the treatment of social phobia. "
02/01/2007 - "Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial."
02/01/1999 - "Controlled studies will be required to further investigate this preliminary finding as well as to compare nefazodone with other pharmacologic treatments of social phobia."
02/01/2007 - "With the exception of the Social Phobia Scale, no significant differences were found in measures of social phobia when comparing the nefazodone and placebo groups. "
|1.||Serotonin (5 Hydroxytryptamine)
|2.||Antidepressive Agents (Antidepressants)
|8.||Risperidone (Risperdal Consta)
|1.||Drug Therapy (Chemotherapy)